Mozobil is a medicine used to mobilise blood stem cells from a patient’s bone marrow so that they can be collected and used later for transplantation in the same patient. Mozobil is used together with the hormone granulocyte-colony stimulating factor (G-CSF) and is only for patients in whom collection of stem cells is difficult. The patients who are given Mozobil are: - adults with lymphoma or multiple myeloma (types of blood cancer); - children from 1 year of age who have lymphoma or solid tumours. Mozobil contains the active substance plerixafor.
Therapeutic Indication
### Therapeutic indication Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.
Therapeutic Area (MeSH)
N/AATC Code
L03AX16
ATC Item
plerixafor
Pharmacotherapeutic Group
Immunostimulants
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Plerixafor | N/A | 普乐沙福 |
EMA Name
Mozobil
Medicine Name
Mozobil
Aliases
N/ANo risk management plan link.
